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Abstract
Stathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly in breast
cancer, have suggested that stathmin may additionally be a predictive marker for response to paclitaxel. We first evaluated
the response to paclitaxel in endometrial cancer cell lines before and after stathmin knock-down. Subsequently we
investigated the clinical response to paclitaxel containing chemotherapy in metastatic endometrial cancer in relation to
stathmin protein level in tumors. Stathmin level was also determined in metastatic lesions, analyzing changes in biomarker
status on disease progression. Knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines
with both naturally higher and lower sensitivity to paclitaxel. In clinical samples, high stathmin level was demonstrated to
be associated with poor response to paclitaxel containing chemotherapy and to reduced disease specific survival only in
patients treated with such combination. Stathmin level increased significantly from primary to metastatic lesions. This study
suggests, supported by both preclinical and clinical data, that stathmin could be a predictive biomarker for response to
paclitaxel treatment in endometrial cancer. Re-assessment of stathmin level in metastatic lesions prior to treatment start
may be relevant. Also, validation in a randomized clinical trial will be important.
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Introduction
Stathmin1 (STMN1 hereafter indicated as ‘stathmin’) is an
18 kD cytosolic phosphoprotein, known to play an important role
in the cell cycle. Stathmin is expressed in all tissues. It is a critical
regulator of microtubule dynamics through its microtubule
destabilizing properties, including both prevention of polymeriza-
tion and active promotion of microtubule depolymerization [1–4].
Phosphorylation of stathmin on four serine residues in the
beginning of the mitotic phase attenuates its destabilizing activities,
allowing cells to form a mitotic spindle; dephosphorylation then
takes place prior to exit of mitosis [1,4]. Stathmin is also involved
in intracellular transport, cell motility, polarity, maintenance of
cell shape and regulation of apoptosis [1].
A biomarker is defined as a ’characteristic that is objectively
measured and evaluated as an indicator of normal biologic
processes, pathogenic processes or pharmacologic responses to a
specified therapeutic intervention [5]. Biomarkers can be divided
in various types, such as prognostic; linked to the prognosis of a
patient independent of treatment, and predictive biomarkers; that
identify patient subpopulations most likely to (not) respond to a
treatment [5]. Thus, reliable predictive biomarkers are of
paramount importance for improved and individualized treat-
ment.
Stathmin is upregulated in many solid cancers, including
endometrial cancer [1,6–14], and its upregulation has been
associated with clinicopathological variables of aggressive disease
such as increased risk of lymph node metastasis [9,15] and poor
survival [6,9,10,12,13,16], confirming stathmins role as a prog-
nostic biomarker.
Presently, few predictive markers are known in human cancers
and even less are clinically applied. In endometrial cancer no
clinically validated predictive markers are yet available [17]. Both
targeted therapies and conventional chemotherapeutic agents are
effective only in a subset of patients [18,19], there is therefore an
urgent need to identify clinically useful predictive markers.
Examples incorporated in the clinic include KRAS mutational
status indicating response to cetuximab and panitumumab in
colorectal cancer [18,20,21], ALK re-arrangement in non-small
cell lung cancer predicting response to crizotinib [18,20,22] and
HER2/Neu amplification or overexpression in breast cancer for
eligibility for trastuzumab treatment [18,20,23].
Taxanes are a group of chemotherapeutic agents frequently
used in the treatment of endometrial carcinoma. Preclinical studies
in breast and prostate cancer and retinoblastoma [24–28] give
preclinical indications that stathmin may be a predictive marker
for response to taxanes in these cancer types. High levels of
stathmin decreased the sensitivity of breast cancer cell lines to
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paclitaxel and vincristine [24] and knock-down of stathmin by
siRNA increased the sensitivity to paclitaxel in both breast [25]
and prostate cells [27]. This impact of stathmin protein level on
treatment response was limited to anti-microtubule agents.
Unfortunately, none of these studies have taken this knowledge
to a next level, integrating the results with clinical data. In
endometrial cancer to our knowledge no studies, preclinical nor
clinical, have explored an association between stathmin level and
response to paclitaxel containing chemotherapy. In this report, we
demonstrate in endometrial carcinoma cell lines, that reduction of
stathmin levels by stathmin knock-down results in improved
response to paclitaxel. We also show for the first time to the best of
our knowledge, that stathmin protein level is associated with
response to paclitaxel containing therapy in clinical samples from
patients with metastatic endometrial carcinoma.
Materials and Methods
Cell lines
Two endometrial cancer cell lines were selected due to the
difference in their sensitivity profile to paclitaxel; Ishikawa (Sigma,
sensitive) and Hec1B (American Type Culture Collection, reduced
sensitive). The Cancer Cell Line Encyclopedia (CCLE) data
confirms the difference in sensitivity [29]. The lines were obtained
in 2009 and authenticity verification by short tandem repeat
(STR) profiling was performed in 2012 [30,31]. The cell lines were
maintained under the conditions recommended by the suppliers.
Cell transfection
Cells were cultured to 50–70% confluence prior to transfection
by lentiviral transduction (Open biosystems, GIPZ lentiviral
shRNAmir). A GIPZ lentiviral shRNA target gene set of 3
(V3LHS_411977; V2LHS_62940; V3LHS_383505) at MOI 2.5
was used. A non-silencing GIPZ lentiviral shRNAmir control
(BV17110_2.80610 8) was used as control. Cells were selected
with puromycin (1 mg/ml) after transfection.
Drugs
Paclitaxel and carboplatin were purchased from Sigma.
Cell line experiments
The cell lines were treated with paclitaxel in increasing
concentrations (range 1–500 nM) for 24 h. As clinically taxanes
are often combined with platinum derivates in endometrial cancer,
we also treated cells with a combination of paclitaxel (in increasing
concentrations (range 1–500 nM) and carboplatin (fixed concen-
tration, 200 mM) for 24 h to observe any synergistic treatment
effects. Cells were subsequently either fixed in 2% formaldehyde
for microscopic evaluation of apoptosis; used in a proliferation
assay (MTS) or processed for immunoblotting. Experiments were
at least performed in triplicate.
For assessment of apoptosis, at least 150 cells were counted in
three different areas in 96-well plates. For proliferation assays,
experiments were performed in triplicates in 96-well plates. Assays
were performed with CellTiter 96H AQueous One Solution Cell
Proliferation Assay (Promega) following instructions from the
manufacturer. The absorbance was recorded at 490 nm using an
ELISA plate reader (TECAN Magellan Sunrise).
Immunoblots were performed according to a standard protocol.
In short, cells were grown and treated in 6-well plates and
harvested in lysisbuffer after 24 h paclitaxel treatment. Proteins
(25 ug) were separated by SDS/PAGE and transferred to a
nitrocellulose membrane (Biorad, Norway). Stathmin and/or
(cleaved) PARP were detected using cleaved PARP (Asp214)
(D64E10) (#5625Cell Signaling), diluted 1:1000 and stathmin
(#3352, Cell Signaling), diluted 1:1000; b-actin served as a
loading control (anti b-actin antibody (AC-15) (ab6276) AbCam),
diluted 1:10000. Alkaline phosphatase conjugated secondary
antibodies were used (Anti-rabbit IgG (Sigma Aldrich A3687):
Anti-mouse IgG (Sigma Aldrich A3562)) and chemoluminiscence
substrate (lumiphos 34150 WB, Thermo scientific) for detection.
Patient series
Patients diagnosed with and treated for endometrial cancer at
Haukeland University Hospital, Bergen, Norway, are after signing
informed consent, prospectively and consecutively included in a
database (population based setting) from 2001 onwards, prevent-
ing selection bias and ensuring optimal data collection for all
patients, as previously reported [14]. Patients have however been
treated following routine guidelines and the clinical samples
Figure 1. Sensitivity of wild-type cell lines to paclitaxel
treatment. A: Microscopic assessment of apoptosis in Ishikawa and
Hec1B wild-type cells after treatment with paclitaxel in the following
dosages: 0 nM, 5 nM, 10 nM, 50 nM, 100 nM, 250 nM and 500 nM.
Results are representative of 5 independent experiments. Standard
errors of the mean are indicated. B: Cell metabolic activity assessed with
a proliferation assay (MTS, Promega) in Ishikawa and Hec1B wild-type
cells after treatment with paclitaxel in the following dosages: 0 nM,
1 nM, 10 nM, 50 nM, 100 nM, 250 nM and 500 nM. Results are
representative of 3 (Ishikawa) and 2 (Hec1B) independent experiments.
doi:10.1371/journal.pone.0090141.g001
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investigated therefore consist of prospectively collected archival
tissue. Clinicopathological data collected include amongst others
FIGO 2009 stage, histological subtype, grade, primary and
adjuvant treatment, and follow up including treatment for
metastatic disease. For the purpose of this study, patients who
received paclitaxel containing chemotherapy (as a routine in our
hospital a combination of paclitaxel and carboplatin) after surgical
treatment for either residual disease or metastasis before April
2011, were studied for treatment response according to RECIST
criteria [32], with last follow-up entry July 2013. Of in total 607
patients in the database, of which 121 had systemic i.e. recurrent
or residual disease, 57 had response data according to RECIST
criteria available; 33 of which were treated with paclitaxel
containing chemotherapy. We defined good response as complete
or partial response (RECIST criteria), and poor response as static
disease or disease progression (RECIST criteria). In addition we
looked at disease specific survival in relation to stathmin level for
all patients with endometrial cancer and specifically for patients
treated for metastatic disease. The mean follow-up in our cohort
was 34 months (range 0–105 months).
Tissue microarray (TMA) construction
TMA’s were generated as previously described and validated in
several studies [33]. The area of highest tumor aggressiveness was
identified on all hematoxylin/eosin slides to ensure tumor
representativity and three (primary tumor) or one (metastasis)
tissue cylinders (0.6 mm diameter each) were mounted in a
recipient block using a custom made precision instrument (Beecher
instruments, silver spring, MD, USA). Formalin fixed paraffin
embedded (FFPE) primary tumor tissue was available in TMAs
from 603 patients for evaluation of stathmin level. From 77
patients with metastases, additional metastatic tissue was available
in TMAs for investigation of stathmin level compared to the
corresponding primary tumor. Too few cases had additional
Figure 2. Ishikawa cell line experiments after stathmin knock-down. A: Immunoblot after transfecting cells with a stathmin lentiviral
shRNAmir (‘stmn kd’) or a non-silencing control (‘non sil’) as well as the parental cell line (wild-type; ‘WT’). Blots were stained for stathmin, and b-actin
for loading control. B: Ishikawa wild-type cell line, non-silencing and stathmin knock-down after treatment with paclitaxel for 24 h in the following
dosages: 0 nM, 5 nM, 10 nM, 50 nM, 100 nM, 250 nM and 500 nM. The level of fragmentation of the cells is indicated in an insert, as a proxy of
progression in the apoptotic process. Diamonds; wild-type, triangles; non-silencing and crosses; stathmin knock-down cells. C: Immunoblot of
Ishikawa wild-type, control (non-silencing) and stathmin knock-down cell lines after treatment with paclitaxel for 24 h in the following dosages: 0 nM,
100 nM and 250 nM. The blot was stained for cleaved PARP and stathmin, with b-actin serving as loading control. D: Left: Ishikawa wild-type (‘WT’)
cell line and Right: Ishikawa stathmin knock-down (‘Stmn kd’) cell line. Microscopic images of cells after treatment for 24 h with 0 nM (top row) or
500 nM (bottom row) paclitaxel also demonstrating increased fragmentation rate for the stathmin knock-down Ishikawa cells (right lower panel)
compared to wild-type (left lower panel).
doi:10.1371/journal.pone.0090141.g002
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evaluable metastatic lesions, obtained prior to the paclitaxel
containing chemotherapy, for stathmin level evaluation, with
response data available according to the RECIST criteria and a
similar prior treatment profile (n = 3) to allow meaningful statistical
analyses of response in relation to biomarker status in metastatic
lesions.
Immunohistochemistry
5 mm thick TMA sections were dewaxed with xylene/ethanol.
Antigen retrieval was done by microwave in TRS pH6 (S1699
Dako Target Retrieval Solution) for 20 minutes. Slides were
blocked for peroxidase (Dako S2023) for 8 minutes and incubated
for 60 minutes with stathmin (Cell signaling #3352), diluted 1:50.
EnVision+ system, HRP secondary antibody (Dako K4011) was
used, followed by DAB+chromogen (DAKO K4011) as detection
system. Slides were counterstained with hematoxylin (Dako,
S2020).
Staining evaluation
Blinded for patient characteristics and outcome, slides were
scored by two authors (HMJW and JT) using standard light
microscopy as previously described [34,35]. The kappa value, as a
measure of reproducibility, was 0.73 in a separate set of 68 slides
scored individually by HMJW and JT. High protein level was
defined as the upper quartile, score 9, in line with previous
publications [15]. In case of multiple metastases with variation in
stathmin level, the lesion with highest level defined the final score
for metastatic lesions.
Statistics
Statistical analyses were performed using PASW18 Statistics
(Predictive Analysis SoftWare, SPSS inc. Chicago, USA). Cate-
gorical variables were evaluated using the Pearson x2-test or
Fisher exact where applicable. Two-sided P-values of ,0.05 were
considered significant. Univariate analyses of time from primary
treatment to death due to endometrial carcinoma (disease specific
survival) were carried out using the Kaplan-Meier method. The
Cox proportional hazards method was used for a multivariate
survival analysis (proportionality assumption checked by log minus
log plot).
Ethics statement
All patients have signed informed consent prior to inclusion in
the study. The study has been approved by the Norwegian Data
Inspectorate (961478-2), the Norwegian Social Science Data
Services (15501) and the local Institutional Review Board
(Regional Committees for Medical and Health Research Ethics;
REKIII nr 052.01).
Figure 3. Hec1B cell line experiments after stathmin knock-down. A: Immunoblot after transfecting cells with a stathmin lentiviral shRNAmir
(‘stmn kd’) or a non-silencing control (‘non sil’) as well as the parental cell line (wild-type; ‘WT’). Blots were stained for stathmin, and b-actin for
loading control. B: Hec1B wild-type cell line, non-silencing and stathmin knock-down lines, after treatment with paclitaxel for 24 h in the following
dosages: 0 nM, 5 nM, 10 nM, 50 nM, 100 nM, 250 nM and 500 nM. C: Left: Hec1B wild-type (‘WT’) cell line and Right: Hec1B stathmin knock-down
(‘Stmn kd’) cell line. Showing microscopic images of cells after treatment for 24 h with 0 nM (top row) or 500 nM (bottom row) paclitaxel
demonstrating increased cell death for the stathmin knock-down Hec1B cells (right lower panel) compared to Hec1B wild-type (left lower panel).
doi:10.1371/journal.pone.0090141.g003
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Results
Response to paclitaxel in endometrial cancer cell lines
Response to paclitaxel varies between endometrial cancer cell
lines [29,36,37]. We show Ishikawa cells are sensitive to paclitaxel
treatment with a high percentage of apoptotic cells after 24 h
treatment (microscopic counting and proliferation assay) as
opposed to Hec1B cells (Fig. 1a and 1b). Combination treatment
of carboplatin and paclitaxel did not result in synergistic treatment
effect (not shown).
Stathmin knock-down by viral transfection
Fluorescence microscopy showed a transfection rate of 70–80%
at the start of experiments, with markedly reduced stathmin levels
in the stathmin knock-down cell lines compared to the control
knock-down and wild-type cell lines (Fig. 2a and 3a).
In both stathmin knock-down cell lines (Ishikawa and Hec1B),
improved response to paclitaxel treatment was observed (Fig. 2b
and 3b). Hec1B cells show a statistically significant increased
apoptotic rate after stathmin knock-down. Possibly due to the
intrinsic higher sensitivity to paclitaxel in Ishikawa cells, knock-
down did not result in a similar large increase in cell death.
However, we noted a clearly increased fragmentation rate in the
treated stathmin knock-down Ishikawa cells opposed to the control
cells, which may be regarded as a sign of further activation of the
apoptotic pathway (insert Fig. 2b). Using immunoblot, we tried to
further validate this enhanced apoptotic pathway activation
demonstrating PARP cleavage at a lower paclitaxel concentration
for Ishikawa after stathmin knock-down compared to controls
(Fig. 2c). Microscopic pictures of Ishikawa and Hec1B wild-type
and stathmin knock-down cells after 24 h paclitaxel treatment with
0 nM (control) and 500 nM are shown in Figures 2d and 3c. We
tested the effect of stathmin knock-down on the sensitivity to
carboplatin monotherapy and paclitaxel-carboplatin combination-
al treatment without observing increased sensitivity or synergistic
effects (not shown).
High stathmin level predicts poor response to paclitaxel
in clinical samples
We then investigated patient tumor samples to see if a similar
association between stathmin level and treatment response could
be observed. Stathmin staining was predominantly cytoplasmic, as
reported in literature [15,38]. Representative pictures from
immunohistochemistry with weak (normal) and strong (high)
stathmin staining are shown in Figure 4a. Excluding metastatic
patients receiving anti-hormonal treatment only, patients with
metastatic disease receiving paclitaxel containing chemotherapy
had similar clinicopathological characteristics as patients treated
differently. Including the patients treated with anti-hormonal
drugs only, predominantly frail elderly patients, clinicopatholog-
Figure 4. Stathmin protein expression in relation to clinical parameters. A: Pictures representative of weak immunohistochemical stathmin
staining (top) and strong (high or pathologic) stathmin staining (bottom) in endometrial carcinoma. Bars (right lower corner) measure 40 mm. B:
Clinical response to paclitaxel for all endometrial carcinoma patients with evaluable disease according to RECIST criteria and separated for normal
versus high stathmin level. Poor response (RECIST: static disease or disease progression) indicated in blue, good response (RECIST: complete or partial
response) indicated in red. C: Comparison of high (pathologic) stathmin protein level in primary and metastatic lesions.
doi:10.1371/journal.pone.0090141.g004
Stathmin Predicts Response in Endometrial Cancer
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e90141
ical characteristics still remained similar, except that this subgroup
was significantly older (Table 1). Patients with normal stathmin
level clearly responded much better (RECIST criteria) to
treatment than patients with high stathmin level (Fig. 4b).
Stathmin level did not predict response to other chemotherapy
regimens or treatment modalities.
Approaching from a different angle, in general, patients with
high stathmin level showed a reduced disease specific survival, in
line with stathmins role as a prognostic biomarker (Fig. 5a).
However, within the subgroup of patients with metastatic disease
treated with paclitaxel containing chemotherapy, disease specific
survival was significantly poorer in those patients with high
compared to normal stathmin (p = 0.03, Fig. 5b). In patients who
received other treatments for metastatic disease, prognosis was
unrelated to stathmin level (p = 0.76, Fig. 5c. To rule out
confounding by known important clinicopathological prognostic
variables, we performed a multivariate survival analysis for both
subgroups to look into the effect of stathmin level on survival after
treatment for metastatic disease, corrected for FIGO stage and
histological subtype. Stathmin protein level remained an indepen-
dent predictor of disease specific survival in the subgroup of
patients that received paclitaxel containing chemotherapy (n= 38,
HR 2.3, CI 1.1–5.2), adjusted for FIGO stage and histological
subtype, but not in the subgroup receiving other therapies (n = 43,
HR 1.1, CI 0.4–2.7).
Discordant biomarker status in primary and metastatic
lesions
The percentage of patients with high stathmin level was
significantly higher in metastases compared to primary lesions
with pathologic (high) levels noted in 18% of the latter (n = 84 of
477 primary lesions with stathmin staining available) compared to
37% in metastatic samples (n = 29 of 79) (Fig. 4c).
In the paired primary-metastasis samples, 35% of metastatic
lesions showed high stathmin level. A discordance of 26% between
metastatic lesions and their primaries was observed. In 16% there
was a change to high level in metastases and in 10% to normal
level.
Discussion
Stathmin protein level has been shown to be a prognostic
marker of aggressive disease in many cancers, including endome-
trial cancer, where high stathmin level in primary tumor identifies
patients at high risk for recurrent disease and lymph node
metastases [6,9,10,12,13,15,16]. The identification and develop-
ment of predictive biomarkers are of paramount importance to
increase treatment efficacy and reduce unnecessary side effects,
not only in targeted therapies but also in chemotherapeutic
regimes, as for both counts that only a subpopulation will respond
well, especially in the metastatic setting, but with currently very
limited tools available to predict these patients [39,40]. None of
the important clinicopathological factors, such as FIGO stage or
histological subtype, are currently known to help distinguish
potential responders from non-responders to paclitaxel containing
chemotherapy in the metastatic setting. Studying large population
based series with high-quality clinical annotation such as our
series, combined with preclinical experiments are a useful and
time-efficient tool to explore potential predictive biomarkers,
which can subsequently be tested in clinical trials.
In line with previous in vitro results in breast cancer, we show in
endometrial cancer cell lines that, independent of the original
stathmin level, sensitivity to paclitaxel increased and thereby
apoptosis expedited after successful stathmin knock-down. This
was shown by direct microscopic counting and in Ishikawa cells
also substantiated by immunoblotting focusing on PARP cleavage.
PARP cleavage is an established indicator of apoptosis, distin-
Table 1. Characteristics of patients receiving paclitaxel or other treatment for metastatic endometrial cancer (n = 78).
Variable Paclitaxel n (%) Other treatment n (%) P-value
FIGO 0.712
I/II 5 (22.7) 15 (26.8)
III/IV 17 (72.3) 41 (73.2)
Histology 0.765
Endometrioid 13 (59.1) 31 (55.4)
Non-endometrioid 9 (40.9) 25 (44.6)
Histological differentiation1 0.365
I/II 6 (27.3) 21 (38.2)
III 16 (72.7) 34 (61.8)
Age (median 66) 0.031
Below/equal to 15 (68.2) 23 (41.1)
Above 7 (31.8) 33 (58.9)
Menopausal status 0.255
Pre/perimenopausal 3 (13.6) 3 (5.4)
Postmenopausal 19 (86.4) 53 (94.6)
Stathmin expression2 0.891
Normal 15 (71.4) 37 (69.8)
High expression (9) 6 (28.6) 16 (30.2)
1 information missing for 1 patient.
2 information missing for 4 patients.
doi:10.1371/journal.pone.0090141.t001
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guishing it from other mechanisms of cell death, such as necrosis.
The increased apoptotic body formation noted by microscopy in
the stathmin knock-down cell lines fits with increased apoptosis
[41,42].
In our prospectively collected, retrospectively analyzed patient
series, we also demonstrated a striking difference in response to
paclitaxel containing chemotherapy comparing patients with
normal to those with high stathmin level, also when correcting
for the most important clinicopathological prognostic variables.
Even when exploring such a large clinical series with endometrial
cancer patients as ours, collected over more than 10 years, with
adequate follow-up and RECIST [32] compliant documentation
of response, ultimately only a smaller number of patients had been
treated with the treatment of interest, underlining the difficulty of
collecting series with adequate patient numbers for specific marker
studies; but at the same time the importance to exploit these large
prospectively collected population based series for predictive
biomarkers suggested in preclinical studies, and explore potential
clinical validity prior to clinical trial stage. The statistically
significant correlation between high stathmin level and poor
paclitaxel response according to RECIST criteria in clinical
samples and the fact that stathmin level has an independent
prognostic value in patients receiving paclitaxel for metastatic
disease, not present in patients who do not, in survival analyses,
supports the likelihood that the level of stathmin level may act not
only as a prognostic marker but also as a predictive marker for
response to paclitaxel treatment in endometrial carcinomas.
Unlike previous studies looking at stathmin as a potential
predictive marker, predominantly in in vitro breast cancer studies,
in this study we were able to test and confirm the association in
clinical samples from patients treated with the drug of interest;
using data from a well-annotated prospectively collected patient
series. Both the preclinical and clinical testing support that
stathmin level influences sensitivity to paclitaxel. We have
explored and excluded that this effect can be generalized to other
chemotherapeutic agents such as carboplatin, also frequently used
in endometrial cancer.
Reporting recommendations for tumor marker prognostic
studies (REMARK) guidelines have been developed with the
aim to improve the methodological quality and reporting
transparency in such studies [43]. The current study has been
performed in accordance to these guidelines to improve the quality
and general validity of its results.
Taxanes, originally isolated from the bark of the yew tree,
belong to the family of anti-microtubule chemotherapeutic agents,
with paclitaxel as their prototype. Simply put, taxanes bind to b -
tubulin, causing microtubules to resist depolymerization, inhibiting
cell cycle progression and promoting mitotic arrest and cell death
[44]. Carboplatin, in contrast, is one of the platinum based agents,
interacting with DNA and interfering with DNA repair. As
stathmin is a critical regulator of microtubule dynamics, taken into
consideration the mode of action of the drugs, the positive effect of
stathmin knock-down on paclitaxel response and the absence of it
to carboplatin sensitivity, is also biologically plausible.
We show a higher proportion of high stathmin level in
metastatic (37%) compared with primary lesions (18%). Discrep-
ancy in stathmin status was noted in a quarter of paired samples,
paralleling findings in e.g. breast cancer where discrepancies
between primary and metastatic lesions are shown in 14–55% and
0–40% for hormone receptors and HER2 respectively [45–47]. In
endometrial cancer, few studies discuss differences in marker status
between primary and metastatic lesions [38,48,49]. Intratumoral
heterogeneity is well described in cancer and a potential
confounding factor in many studies, irrespective of using full-
tissue slides or TMA. Inter-observer variation is unlikely to be the
sole explanation for these described differences. Also, a recent
study assessing mutation status, a method considered less
subjective than immunohistochemical scoring, in multiple meta-
static lesions from one patient with renal cell carcinoma, support
that detected biomarker changes from primary to metastatic
lesions are real and may be related to and relevant for tumor
progression [39]. The changes in biomarker status from primary to
metastatic lesions support the need for repeated biopsies in
metastatic lesions, to better relate therapy response to potential
predictive biomarkers but also to only offer therapies with likely
positive effect when predictive biomarkers are available
[47,50,51]. For breast cancer, The American society of clinical
oncology (ASCO) advised in 2007 already that for hormone
receptor status, testing should be considered to be repeated in
Figure 5. Disease specific survival after primary treatment for
endometrial carcinoma patients (Kaplan-Meier curves) related
to stathmin protein expression by IHC in primary tumor. A: All
patients with complete data (n = 476). Number of disease specific
events between brackets. B: All patients with metastatic disease who
received paclitaxel treatment (n = 38). Number of disease specific events
between brackets. C: All patients with metastatic disease who received
different treatments (n = 43). Number of disease specific events
between brackets.
doi:10.1371/journal.pone.0090141.g005
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metastatic disease if the results were to influence patient
management [52].
Conclusion
These results, including preclinical data and for the first time
data from clinical samples, support that stathmin may be a
predictive biomarker for the response to paclitaxel treatment in
endometrial cancer. However, confirmatory studies, ideally from
randomized clinical trials are needed. The biomarker discordance
on tumor progression is in line with other studies on tumor
biomarker heterogeneity and supports the need for repeated
biopsy in metastatic disease.
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